| Report ID | 278172 |
| Drug Identification Number | 02529599 |
| Brand name | AZACITIDINE FOR INJECTION |
| Common or Proper name | AZACITIDINE FOR INJECTION |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | AZACITIDINE |
| Strength(s) | 100MG |
| Dosage form(s) | POWDER FOR SUSPENSION |
| Route of administration | SUBCUTANEOUS |
| Packaging size | 1LYVI |
| ATC code | L01BC |
| ATC description | ANTIMETABOLITES |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | |
| Actual start date | 2026-02-16 |
| Estimated end date | 2026-03-06 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2026-03-02 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 4600 RUE ARMAND-FRAPPIER SAINT-HUBERT, QUEBEC CANADA J3Z 1G5 |
| Company contact information | 1 800-361-3062 |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2026-03-02 | French | Compare |
| v3 | 2026-03-02 | English | Compare |
| v2 | 2026-02-16 | French | Compare |
| v1 | 2026-02-16 | English | Compare |
Showing 1 to 4 of 4